Renaissance Capital published its 3Q 2026 U.S. IPO Market Review on October 1, 2026, reporting 30 U.S. initial public offerings that raised a combined $32.8Bn in the third quarter. Measured on proceeds, the quarter ran well ahead of the ten-year third-quarter average of $12.1Bn. Measured on issuer count, it ran well behind the same ten-year average of 49 deals. That split is the quarter’s defining feature, and it matters more to issuers than either figure read alone.

The reconciliation sits in one listing. Renaissance attributes $26.5Bn of the quarter’s proceeds to SK hynix’s U.S. offering, which it describes as the largest U.S. listing since SpaceX. Excluding that deal, third-quarter proceeds were $6.2Bn across the remaining issuers. For a private company weighing a listing, the quarter appears to have offered a narrow and selective window, one that accommodated scale more readily than it accommodated the median candidate.

Third Quarter Issuance Overview

Of the 30 deals, 18 raised $100.0MM or more, roughly half the 38 that cleared that threshold in the second quarter. Median deal size was approximately $211.0MM, which Renaissance attributes in part to stricter exchange listing rules that kept micro-cap issuers largely sidelined. Healthcare was the most numerous sector, with nine IPOs, all biotechnology, raising a combined $2.4Bn. Technology ranked second by deal flow but first by proceeds, at approximately $27.6Bn.

Seven companies chose a direct listing, which Renaissance describes as the busiest quarter on record for that structure. Renaissance excludes direct listings from its return statistics and reports that the group traded very poorly, with all but one finishing below its opening price. That pattern suggests that avoiding a marketed process does not avoid the valuation question and may instead move price discovery into the secondary market, where the issuer has less influence.

ICR counted the same quarter differently, reporting approximately 20 IPOs raising about $33.0Bn in its Q3 2026 Equity Capital Markets Review published October 2, 2026. The gap sits in inclusion criteria rather than in the dollars, since the two houses apply different deal-size floors and treat SPACs and direct listings differently. The figures here are Renaissance’s unless stated otherwise.

Concentration of Proceeds

Renaissance reports that the ten largest IPOs raised a combined $31.2Bn, or approximately 95.0% of total proceeds, with SK hynix alone accounting for roughly 80.0%. One cross-listing carrying four-fifths of total volume points to two markets rather than one. The first clears very large, well-understood assets at scale, and the second leaves everyone else to accept whatever the book will bear.

The concentration also distorts the sponsor data. Renaissance reports $29.7Bn of private equity-backed proceeds across seven IPOs, mostly from SK hynix; excluding it, private equity proceeds were approximately $3.2Bn, below five of the past eight quarters. For sponsors holding assets outside the memory and AI infrastructure themes, the quarter offers limited evidence that a listing would have cleared on acceptable terms.

Aftermarket Performance and Pricing Discipline

The average third-quarter IPO returned -0.1% from offer on Renaissance’s figures, with a first-day gain of 6.2% given back through an aftermarket return of -5.7%. Approximately 30.4% of deals priced below their marketed range, which Renaissance characterizes as a high-water mark for recent periods, and 39.1% recorded a negative first-day return.

The Renaissance IPO Index fell 11.5% in the quarter against a 2.3% gain for the S&P 500, though the IPO index remained ahead of the broader benchmark for the year to date, at 15.9% against 12.7%. The combination of a negative cohort return, a below-range share above 30.0% and a sharp index drawdown suggests that buyers were present but price-sensitive. Demand appears not to have disappeared so much as repriced.

The Pipeline and the Decision to Wait

Renaissance counted 61 initial filings in the quarter, compared to 30 pricings, 21 withdrawals and three postponements. That churn leaves 221 companies on file to raise $21.7Bn, including an active pipeline of 85 names updated within the past 90 days. Anthropic is currently expected to headline fourth-quarter activity, while OpenAI is reportedly waiting until 2027.

The deferrals point to a deliberate choice rather than a closed market. Issuers with a choice appear to have concluded that the discount required to clear a book in September was larger than the cost of waiting a quarter. That calculation is broadly rational when a pipeline is deep and a funding need is not immediate, and it is one reason a thin third quarter does not necessarily imply a thin fourth.

Broader Implications for Capital Markets

The IPO channel was the narrow part of equity capital markets in the quarter rather than the whole of it. ICR reports convertible issuance exceeding $40.0Bn in the third quarter, enough to push year-to-date volume past 2025’s full-year record. It also counts approximately $50.0Bn raised across follow-ons and block trades, compared to roughly $34.0Bn a year earlier. Those are ICR’s figures on ICR’s criteria, and the direction is consistent with capital remaining available to issuers that already had a public price.

For a private company weighing a listing against a sale or a private round, that asymmetry matters. An IPO in this market appears to require either genuine scale or a story the buyside already underwrites, and the median candidate at roughly $211.0MM is likely to be asked for a concession on price, on range or on both. A sale process puts valuation in the hands of a few informed counterparties rather than a book built into a drawdown, and a private round defers the question without crystallizing a mark. Neither path is automatically preferable, but the quarter appears to have widened the distance between the three rather than narrowed it.

Conclusion

Renaissance’s data describe a market that raised $32.8Bn while conducting 30 offerings, and much of what matters sits between those two numbers. One cross-listing supplied roughly four-fifths of the proceeds, issuer count ran at about 60.0% of the ten-year third-quarter average, and nearly a third of deals priced below range. However, a deep pipeline, an expected fourth-quarter mega offering and the index’s year-to-date lead over the S&P 500 all argue against reading the quarter as a closed window. For companies now on file, the third quarter reads as evidence that access was available at a price, with that price set largely by scale and familiarity rather than by fundamentals alone.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan’s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.